Anti mullerian hormone: Ovarian response indicator in young patients receiving long GnRH agonist protocol for ovarian stimulation

Objective: Anti Mullerian hormone (AMH) is gaining place as ovarian marker, chiefly in infertility assistance. We explored its correlation with oocytes retrieval after long GnRH agonist protocol for stimulation, in younger and older infertile population.Methods: This retrospective analysis compiled data of 166 females, receiving ICSI treatment from June 2014 to March 2015. Serum FSH, LH, Estadiol, AMH and antral follicle count were assessed. Outcomes were measured as good (5 to 19 oocytes) and bad responders.Results: Higher discriminatory power of AMH (AUROC; 0.771; p \u3c 0.05) was seen in comparison to FSH (0.692; p \u3c 0.05) and AFC (0.690; p \u3c 0.01). AMH reported strongest association with oocyte retrieved (odds ratio of 15.06). Subgroup analysis reported 68.6 % risk of bad response with AMH levels of less than 1.37ng/ml. This association was observed more significant in young infertile patients \u3c35 year of age (r=0.245; p=0.012) versus older population \u3e35 year (r=0.169; p\u3e0.05).Conclusion: Our study reaffirms that serum AMH correlates well with oocytes retrieved, particularly in females younger than 35 years. We suggest incorporation of AMH in baseline assessment of infertile females, who are falsely advised to postpone interventions based on their age and normal FSH levels